Lannett Encouraged By Levothyroxine Development In Florida
Feb 13th 2008Drug InformationEndocrinology
Lannett Company, Inc. (AMEX: LCI) said it is encouraged by a legal development in Florida that could remove generic Levothyroxine Sodium from the state’s negative drug formulary. An administrative judge in Florida recently found that the inclusion of Levothyroxine on the state’s negative drug formulary is an invalid exercise of legislative authority and that the product should be removed from the negative formulary.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
